Orlando Medical News features GID BIO's cellular therapy and pivotal/Phase III clinical trial

GID BIO rekindles capital raise after launching Phase 3 trial for osteoarthritis - CEO by Deborah Balshem of Mergermarket GID BIO, a privately held cellular medicine company, has restarted a...

Patient enrollment is open for a pivotal/Phase III clinical trial to test GID BIO’s cellular therapy for knee osteoarthritis   GID BIO’s point-of-care cellular therapy is being tested to treat...

Shrock Clinical Research, the only approved site in Florida, joins GID BIO’s pivotal, FDA-compliant clinical trial for knee osteoarthritis   Kevin Shrock, MD, FAAOS, CPI, a South Florida practicing orthopaedic...

San Antonio Business Journal features GID BIO's cellular therapy and pivotal/Phase III clinical trial principal investigator, Dr. Jaime Garza: "On the forefront of new cell therapy research, an Alamo City surgeon has a key role in moving new medical technology to market"

  Statements in this article are the perspective of the San Antonio Business Journal.

Jaime Garza drives innovation in Texas as principal investigator of a pivotal/Phase III trial for GID BIO’s cellular therapy As the number of companies developing and producing medical devices rises...

Patient enrollment begins at Tulane University School of Medicine for GID BIO’s pivotal/Phase III clinical trial testing cellular therapy for knee osteoarthritis Jaime Garza, MD, DDS, FACS, Professor of Orthopaedics,...

New Jersey Regenerative Institute begins enrolling patients for GID BIO’s pivotal/Phase III clinical trial testing cellular therapy for knee osteoarthritis Gerry Malanga, M.D., recent president of Interventional Orthobiologics Foundation, is...

GID BIO begins pivotal/Phase III clinical trial patient enrollment process at Texas Center for Cell Therapy and Research in San Antonio This summer, the FDA cleared our stromal-vascular-fraction cellular therapy...

Late-stage biotech GID BIO wins funding from Richard King Mellon Foundation...

Late-stage biotech GID BIO wins funding from Richard King Mellon Foundation to study regenerative medicine as a potential therapeutic for severe respiratory distress Study to treat hospitalized COVID-19 patients applies...

Denver Business Journal features GID BIO...

Denver Business Journal features GID BIO: “Colorado biotech firm’s new cell therapy could eliminate the need for knee replacements” As the total number of confirmed COVID-19 cases surpasses five million...

Denver Business Journal features GID BIO: “Colorado biotech firm’s new cell therapy could eliminate the need for knee replacements”

Statements in this article are the perspective of the Denver Business Journal.